ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Wilba32
|
168 |
101K |
19 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
168
|
101K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Wilba32
|
154 |
49K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
49K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
180K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
5 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
180K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Wilba32
|
9.9K |
3.0M |
11 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
9.9K
|
3.0M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Wilba32
|
9.9K |
3.0M |
4 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
9.9K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
16 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
180K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
5 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
180K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
What happens if there is attempt to take over?
|
|
Wilba32
|
16 |
6.1K |
14 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
16
|
6.1K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
8 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
16 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
4 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
10 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
180K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
180K |
4 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
180K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
3 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
761
|
305K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
9 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
9 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
19 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
19
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
4 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
761
|
305K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
4 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
761
|
305K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
11 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
761
|
305K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
8 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
761
|
305K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
761
|
305K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
761 |
305K |
6 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
761
|
305K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Wilba32
|
9.9K |
3.0M |
16 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
9.9K
|
3.0M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Wilba32
|
9.9K |
3.0M |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
9.9K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Wilba32
|
23 |
8.0K |
7 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
23
|
8.0K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Wilba32
|
17K |
6.7M |
21 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
17K
|
6.7M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Wilba32
|
168 |
101K |
6 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
168
|
101K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Wilba32
|
23 |
8.0K |
9 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
23
|
8.0K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Wilba32
|
168 |
101K |
7 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
168
|
101K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
Wilba32
|
31 |
10K |
7 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
31
|
10K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
Wilba32
|
31 |
10K |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
31
|
10K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Wilba32
|
78 |
25K |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
25K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Wilba32
|
78 |
25K |
8 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
25K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Wilba32
|
78 |
25K |
6 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
25K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
AA
|
|
Wilba32
|
13 |
4.7K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
13
|
4.7K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Wilba32
|
362 |
120K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
362
|
120K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Wilba32
|
152 |
47K |
27 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
47K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Wilba32
|
362 |
120K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
362
|
120K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
Wilba32
|
209 |
51K |
20 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
51K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Wilba32
|
62 |
23K |
10 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
62
|
23K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Wilba32
|
62 |
23K |
3 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
62
|
23K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Wilba32
|
62 |
23K |
4 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
62
|
23K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Wilba32
|
62 |
23K |
17 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
62
|
23K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Wilba32
|
362 |
120K |
0 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
362
|
120K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Wilba32
|
362 |
120K |
16 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
362
|
120K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Wilba32
|
272 |
103K |
8 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
272
|
103K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
Wilba32
|
323 |
78K |
4 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
323
|
78K
|
4
|
|